Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
——

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-14.5%
Enterprise value$1.21B+2.6%
P/E183.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Pacira BioSciences, Inc. (PCRX) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $49K in Q1 2026.
How has Pacira BioSciences, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
Pacira BioSciences, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 28.9% year-over-year, from $38K to $49K.
What is the long-term trend for Pacira BioSciences, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -16.0% compound annual growth rate (CAGR), from $31K to $13K.